vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Climb Global Solutions, Inc. (CLMB). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($193.8M vs $139.2M, roughly 1.4× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 3.6%, a 31.9% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (19.8% vs 18.4%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (44.8% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
ADMA vs CLMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $193.8M |
| Net Profit | $49.4M | $7.0M |
| Gross Margin | 63.8% | 15.4% |
| Operating Margin | 45.1% | 4.9% |
| Net Margin | 35.5% | 3.6% |
| Revenue YoY | 18.4% | 19.8% |
| Net Profit YoY | -55.9% | -0.1% |
| EPS (diluted) | $0.20 | $1.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $193.8M | ||
| Q3 25 | $134.2M | $161.3M | ||
| Q2 25 | $122.0M | $159.3M | ||
| Q1 25 | $114.8M | $138.0M | ||
| Q4 24 | $117.5M | $161.8M | ||
| Q3 24 | $119.8M | $119.3M | ||
| Q2 24 | $107.2M | $92.1M | ||
| Q1 24 | $81.9M | $92.4M |
| Q4 25 | $49.4M | $7.0M | ||
| Q3 25 | $36.4M | $4.7M | ||
| Q2 25 | $34.2M | $6.0M | ||
| Q1 25 | $26.9M | $3.7M | ||
| Q4 24 | $111.9M | $7.0M | ||
| Q3 24 | $35.9M | $5.5M | ||
| Q2 24 | $32.1M | $3.4M | ||
| Q1 24 | $17.8M | $2.7M |
| Q4 25 | 63.8% | 15.4% | ||
| Q3 25 | 56.3% | 15.9% | ||
| Q2 25 | 55.1% | 16.5% | ||
| Q1 25 | 53.2% | 16.9% | ||
| Q4 24 | 53.9% | 19.3% | ||
| Q3 24 | 49.8% | 20.3% | ||
| Q2 24 | 53.6% | 20.2% | ||
| Q1 24 | 47.8% | 18.4% |
| Q4 25 | 45.1% | 4.9% | ||
| Q3 25 | 38.0% | 4.3% | ||
| Q2 25 | 35.1% | 5.0% | ||
| Q1 25 | 30.4% | 3.5% | ||
| Q4 24 | 32.6% | 7.2% | ||
| Q3 24 | 33.1% | 7.1% | ||
| Q2 24 | 36.6% | 4.6% | ||
| Q1 24 | 26.7% | 3.8% |
| Q4 25 | 35.5% | 3.6% | ||
| Q3 25 | 27.1% | 2.9% | ||
| Q2 25 | 28.1% | 3.7% | ||
| Q1 25 | 23.4% | 2.7% | ||
| Q4 24 | 95.2% | 4.3% | ||
| Q3 24 | 30.0% | 4.6% | ||
| Q2 24 | 29.9% | 3.7% | ||
| Q1 24 | 21.7% | 3.0% |
| Q4 25 | $0.20 | $1.51 | ||
| Q3 25 | $0.15 | $1.02 | ||
| Q2 25 | $0.14 | $1.30 | ||
| Q1 25 | $0.11 | $0.81 | ||
| Q4 24 | $0.45 | $1.52 | ||
| Q3 24 | $0.15 | $1.19 | ||
| Q2 24 | $0.13 | $0.75 | ||
| Q1 24 | $0.08 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $36.6M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $116.6M |
| Total Assets | $624.2M | $460.2M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $36.6M | ||
| Q3 25 | $61.4M | $49.8M | ||
| Q2 25 | $90.3M | $28.6M | ||
| Q1 25 | $71.6M | $32.5M | ||
| Q4 24 | $103.1M | $29.8M | ||
| Q3 24 | $86.7M | $22.1M | ||
| Q2 24 | $88.2M | $48.4M | ||
| Q1 24 | $45.3M | $43.6M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.2M |
| Q4 25 | $477.3M | $116.6M | ||
| Q3 25 | $431.2M | $109.3M | ||
| Q2 25 | $398.3M | $105.2M | ||
| Q1 25 | $373.4M | $95.6M | ||
| Q4 24 | $349.0M | $90.6M | ||
| Q3 24 | $231.9M | $87.7M | ||
| Q2 24 | $188.3M | $79.8M | ||
| Q1 24 | $153.7M | $76.4M |
| Q4 25 | $624.2M | $460.2M | ||
| Q3 25 | $568.7M | $376.1M | ||
| Q2 25 | $558.4M | $420.7M | ||
| Q1 25 | $510.6M | $370.1M | ||
| Q4 24 | $488.7M | $469.2M | ||
| Q3 24 | $390.6M | $371.9M | ||
| Q2 24 | $376.4M | $302.8M | ||
| Q1 24 | $350.9M | $298.3M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-11.9M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | -1.70× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-11.9M | ||
| Q3 25 | $13.3M | $22.2M | ||
| Q2 25 | $21.1M | $-2.2M | ||
| Q1 25 | $-19.7M | $8.5M | ||
| Q4 24 | $50.2M | $16.0M | ||
| Q3 24 | $25.0M | $-3.6M | ||
| Q2 24 | $45.6M | $7.3M | ||
| Q1 24 | $-2.2M | $14.0M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | -1.70× | ||
| Q3 25 | 0.36× | 4.73× | ||
| Q2 25 | 0.62× | -0.37× | ||
| Q1 25 | -0.73× | 2.30× | ||
| Q4 24 | 0.45× | 2.29× | ||
| Q3 24 | 0.70× | -0.66× | ||
| Q2 24 | 1.42× | 2.13× | ||
| Q1 24 | -0.12× | 5.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
CLMB
| Distribution Segment | $187.9M | 97% |
| Solutions Segment | $6.0M | 3% |
